(CIX: WRAL30)  1,030.19  down arrow-22.86  (-2.17 %)  Updated: 08:10 PM EST, Feb 05 2016
(NQ: Apple)  94.02  down arrow-2.58  (-2.67 %)  Updated: 08:10 PM EST, Feb 05 2016
(NY: QUINTILES)  57.50  down arrow-2.03  (-3.41 %)  Updated: 06:40 PM EST, Feb 05 2016
(OP: BASF SE)  65.86  down arrow-0.41  (-0.62 %)  Updated: 05:20 PM EST, Feb 05 2016
(NQ: BioCryst)  6.14  down arrow-0.36  (-5.54 %)  Updated: 08:10 PM EST, Feb 05 2016
(NQ: BioDelivery)  3.73  down arrow-0.24  (-6.05 %)  Updated: 08:10 PM EST, Feb 05 2016
(NQ: CEMP)  18.61  up arrow+0.6  (3.33 %)  Updated: 08:10 PM EST, Feb 05 2016
(NQ: Cisco)  22.89  down arrow-0.65  (-2.76 %)  Updated: 08:10 PM EST, Feb 05 2016
(NQ: Cree)  28.88  down arrow-0.67  (-2.27 %)  Updated: 08:10 PM EST, Feb 05 2016
(NQ: DARA)  0.88    (0 %)  Updated: 08:10 PM EST, Dec 04 2015
(NY: EMC)  24.55  down arrow-0.2  (-0.81 %)  Updated: 06:40 PM EST, Feb 05 2016
(NQ: Extreme Networks)  2.59  up arrow+0.01  (0.39 %)  Updated: 08:10 PM EST, Feb 05 2016
(NQ: Facebook)  104.07  down arrow-6.42  (-5.81 %)  Updated: 08:10 PM EST, Feb 05 2016
(NY: GLAXOSMITHKLINE)  40.76  down arrow-0.22  (-0.54 %)  Updated: 06:40 PM EST, Feb 05 2016
(NQ: Alphabet)  683.57  down arrow-24.44  (-3.45 %)  Updated: 08:10 PM EST, Feb 05 2016
(NY: IBM)  128.57  up arrow+0.92  (0.72 %)  Updated: 06:40 PM EST, Feb 05 2016
(NY: LH)  106.17  down arrow-2.16  (-1.99 %)  Updated: 06:40 PM EST, Feb 05 2016
(OP: Lenovo Group)  17.00  down arrow-0.3  (-1.73 %)  Updated: 05:20 PM EST, Feb 05 2016
(NY: MRK)  49.38  up arrow+0.79  (1.63 %)  Updated: 06:40 PM EST, Feb 05 2016
(NQ: Microsoft)  50.16  down arrow-1.84  (-3.54 %)  Updated: 08:10 PM EST, Feb 05 2016
(NQ: NetApp)  22.64  up arrow+0.06  (0.27 %)  Updated: 08:10 PM EST, Feb 05 2016
(NY: NOVARTIS AG)  74.33  down arrow-0.73  (-0.97 %)  Updated: 06:40 PM EST, Feb 05 2016
(OP: Novozymes A/S)  42.47  down arrow-0.71  (-1.63 %)  Updated: 05:20 PM EST, Feb 05 2016
(NY: Pfizer)  29.03  up arrow+0.03  (0.1 %)  Updated: 06:40 PM EST, Feb 05 2016
(NQ: Pozen)  5.94  down arrow-0.43  (-6.75 %)  Updated: 08:10 PM EST, Feb 05 2016
(NY: Red Hat)  63.14  down arrow-5.48  (-7.99 %)  Updated: 06:40 PM EST, Feb 05 2016
(NQ: BBRY)  7.09  down arrow-0.31  (-4.19 %)  Updated: 08:10 PM EST, Feb 05 2016
(NQ: Salix)  172.81    (0 %)  Updated: 08:10 PM EDT, Apr 01 2015
(NQ: SQI)  12.42  down arrow-0.43  (-3.35 %)  Updated: 08:10 PM EST, Feb 05 2016

Posts tagged “Quintiles”

9:37 a.m. Thursday

Quintiles exec on immunotherapy: 'It's working'

Cancer research  In observance of Feb. 4 as "World Cancer Day," Terry Murdock, the head of the Oncology Center of Excellence at Quintiles, writes in a blog that "there is much to celebrate" this year in the fight against cancer.

Updated January 14

Premium Lock Quintiles defends company, CROs despite stock drops

With "apathetic" attitudes helping drive down life science industry stocks as part of a general market spiral, Quintiles CEO Tom Pike took to the airways Wednesday evening to defend his company and the biotech-related sector.

Quintiles' dropping stock Quintiles' dropping stock

Updated January 14

Premium Lock Report: CRO industry to grow at 6% a year through 2022

Medical research The contract research organization business, which has a big hub in the Triangle with numerous major players based in the region, is headed toward seven years of plenty, according to a new report.

Updated January 7

Premium Lock Quintiles hits CES, talking mHealth with Durham startup Validic

Quintiles            As digital health becomes more common in these days of emerging electronic medical records, wearable health devices and more, Quintiles is joining the growing number of companies seeking to capitalize on the world's biggest tech show: CES in Las Vegas. And Durham-based Validic exec will be leading the discussion in which Quintiles is participating.

December 3, 2015

Premium Lock INC Research wins prestigious award as top CRO

INC Research INC Research, a fast-growing life science contract research organization, is the winner of the prestigious Scrip Award as the top CRO for 2015. Quintiles and PPD were also finalists.

Updated November 24, 2015

Premium Lock Validic signs Quintiles as a client, effective immediately

Validic Quintiles becomes the latest client of Validic. The CRO will leverage Validic's platform to enrich the research experience for biopharmaceutical customers, researchers and patients.

November 10, 2015

Premium Lock Quintiles contributes open source code to ResearchKit

Quintiles            Quintiles has added open source code to ResearchKit framework, making it easier for developers to leverage health care data. The source code is available on GitHub.

Tags: Quintiles
November 5, 2015

Premium Lock Quintiles executive chairman Dennis Gillings to step down

Dennis Gillings, Quintiles Founder (2015) Dennis Gillings, the founder and executive chairman of Quintiles will retire at the end of 2015. He'll remain on the board of directors. Jack M. Greenberg will succeed him.

Tags: Quintiles
October 28, 2015

Premium Lock Quintiles Q3 earnings top analysts estimates

Quintiles            Quintiles Transactional Holdings (NYSE:Q) reported third quarter earnings of $117.58 million or 94 cents a share, beating analyst expectations of 81 cents a share and a 44.6 percent increase compared to the same period last year.

October 20, 2015

Premium Lock Quintiles names new COO and CFO

Quintiles            Quintiles has named Kevin Gordon, currently serving as executive vice president, Operations and chief financial officer (CFO), has been promoted to chief operating officer (COO). The company also said Michael McDonnell is expected to join Quintiles in December 2015 as executive vice president, chief financial officer (CFO).

Tags: Quintiles
October 12, 2015

Premium Lock Quintiles wins clinical research site award

Quintiles            Quintiles has been awarded the Society for Clinical Research Sites' (SCRS) 2015 Clinical Research Organization Eagle Award.

September 29, 2015

Premium Lock Beyond Statins: 2015 was a benchmark year for lipid lowering research

Li-Jung Tai, associate medical director, Quintiles Today is World Heart Day and to celebrate, Quintiles will turn its Durham building red. It also offers this look at new choices in lipid lowering drugs and what may be coming in the future.

September 28, 2015

Premium Lock Quintiles named market leader in Phase IV services

Quintiles            Quintiles has been named the market leader in Phase IV services for the third year in a row. That's according to the 2015 CRO Quality Benchmarking - Phase IV Service Providers Report from Industry Standard Research (ISR).

Updated September 21, 2015

Premium Lock Alzheimer's Research: 100 years in the making

Alzheimer's inforgraphic Today (Monday, Sept. 21) is World Alzheimer's Day and Durham-based Quintiles offers, among its day-long events, this assessment of the problem and the progress made with hope for a solution.

Updated September 18, 2015

Premium Lock NC Economic development package; Most innovative universities; Alzheimer's Day; startup hiring

Bulldog In today's Bulldog update of technology news: NC economic development package passes; 3 NC universities on most innovative list; Quintiles plans for Alzheimer's Day Monday; health IT startup to expand.

Updated July 31, 2015

Premium Lock 14M PCs run Windows 10; SciQuest profitable; Quintiles investors selling $500M in shares; Google's 'no' to right-to-be-forgotten; LinkedIn tumbles

Bulldog Bulletin In today's wrapup of technology and life science news: Microsoft says 14 million computers are running Windows 10; SciQuest turns a profit; Quintiles investors are selling $500 million in shares; Google says "no" to right-to-be-forgotten in France; and LinkedIn shares tumble despite good quarterly results.

Updated July 29, 2015

Premium Lock Quintiles beats Street expectations despite impact of stronger dollar

Quintiles            Quintiles beats Wall Street analysts' expectations for revenue and earnings in the second quarter despite the impact of a stronger dollar on its overseas business. Will its stock rally on the news?

July 6, 2015

Premium Lock 'Humbled' veteran Quintiles exec gears up for new role as Q2 CEO

Q2 Solutions, the new life science services subsidiary launched by Quintiles and Quest Diagnostics, has a familiar face leading it as CEO: Costa Panagos, who has worked at Quintiles for the past 15 years. So why give up corporate security to take the new job? How does he feel about it? And what does Q2 offer in terms of improving healthcare? WTW Insiders get the exclusive details.

Costa Panagos Costa Panagos

Updated July 3, 2015

Premium Lock Will there be layoffs as well as new jobs as Quintiles' Q2 launches?

DNA       Quintiles' new joint venture with Quest formally launched Thursday with a work force of some 2,000 people. But will there be layoffs due to any overlap in job functions? Might there also be new jobs created? Let's take a look.

Updated July 2, 2015

Premium Lock Quintiles, Quest formally launch new clinical lab, drug testing company

Q2 Solutions, or "Q Squared Solutions," is formally launching today as a new clinical trials laboratory company owned by Quintiles and Quest Diagnostics. The new venture is led by a former Quintiles executive. The new company kicks off with 2,000 employees.

Costa Panagos Costa Panagos

Techwire Inside Partners
The Skinny: A Blog by Rick Smith